Regulus Therapeutics
RGLS
$2.42
Share price
6.61%
Change (1 day)
79.26%
Change (1 year)
Categories
Regulus Therapeutics (RGLS) - Total liabilities
Total liabilities on the balance sheet as of September 2023 : $9.48 M
According to Regulus Therapeutics's latest financial reports the company's total liabilities are $9.48 M. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Regulus Therapeutics - Total liabilities on balance sheet (from 2011 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2022-12-31 | $13.42 M | -0.53% |
| 2021-12-31 | $13.49 M | 16.57% |
| 2020-12-31 | $11.57 M | -47.53% |
| 2019-12-31 | $22.06 M | -34.68% |
| 2018-12-31 | $33.78 M | -20.69% |
| 2017-12-31 | $42.59 M | -4.47% |
| 2016-12-31 | $44.58 M | 162.19% |
| 2015-12-31 | $17 M | -56.91% |
| 2014-12-31 | $39.46 M | 33.3% |
| 2013-12-31 | $29.6 M | -28.53% |
| 2012-12-31 | $41.42 M | -50.9% |
| 2011-12-31 | $84.37 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | $57.61 B | 607,119.65% | 🇫🇷 France |
 Biogen BIIB | $12.04 B | 126,854.05% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $65.67 B | 692,079.60% | 🇺🇸 USA |
 AstraZeneca AZN | $61.95 B | 652,861.64% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $58.82 B | 619,896.84% | 🇬🇧 UK |
 Sangamo Therapeutics
SGMO | $82.43 M | 768.81% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | $4.05 B | 42,590.98% | 🇺🇸 USA |